Affimed stops enrolling multiple tumor types as data disappoint but forges ahead in other settings

Affimed is slashing the list of opportunities open to its bispecific innate cell engager AFM24. | Affimed is slashing the list of opportunities open to its bispecific innate cell engager AFM24. The failure of data in multiple tumor types to clear its bar for continuation drove the biotech to narrow its focus to lung cancer—but there are signs of encouragement in that setting and for lead candidate AFM13.